drug sensitivity data (ctd^2) (Broad Institute Inc)
90
Structured Review
Broad Institute Inc
drug sensitivity data (ctd^2)
Drug Sensitivity Data (Ctd^2), supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ctd+data/cancer+lines+ctd2/pm37749246-249-21-7
Average 90 stars, based on 1 article reviews
Drug Sensitivity Data (Ctd^2), supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ctd+data/cancer+lines+ctd2/pm37749246-249-21-7
Average 90 stars, based on 1 article reviews
drug sensitivity data (ctd^2) - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
other:Article Title: MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57 Kip2 targeting Article Snippet: Although this point has been clarified in the above response to point 3, we performed Pearson correlation analysis taking advantage of the DepMap portal (https://depmap.org/portal/) using the 23Q2 public dataset for gene expression and Drug Sensitivity Area Under the Curve (AUC) dataset for drug sensitivity data, which includes 721 cancer lines (CTD2, Broad Institute) (Ancillary Figures 10a,b for Reviewers). Article Title: Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na) Article Snippet: We selected data generated by the Broad Institute CTD^2 Center originally published via the Cancer Therapeutics Response Portal (CTRP) [ , ] to plot rigosertib sensitivity (AUC, area under the curve) against different cancer lineages. CRISPR:Article Title: Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities. Article Snippet: The paradigm of cancer-targeted therapies has focused largely on inhibition of critical pathways in cancer.. Conversely, conditional activation of signaling pathways as a new source of selective cancer vulnerabilities has not been deeply characterized.. In this study, we sought to systematically identify context-specific gene-activation-induced lethalities in cancer. Expressing:Article Title: Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities. Article Snippet: The paradigm of cancer-targeted therapies has focused largely on inhibition of critical pathways in cancer.. Conversely, conditional activation of signaling pathways as a new source of selective cancer vulnerabilities has not been deeply characterized.. In this study, we sought to systematically identify context-specific gene-activation-induced lethalities in cancer. Protein Array:Article Title: Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities. Article Snippet: The paradigm of cancer-targeted therapies has focused largely on inhibition of critical pathways in cancer.. Conversely, conditional activation of signaling pathways as a new source of selective cancer vulnerabilities has not been deeply characterized.. In this study, we sought to systematically identify context-specific gene-activation-induced lethalities in cancer. Mutagenesis:Article Title: Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma Article Snippet: .. We combined the data for the TP53 mutation status of a large cohort of cancer cell lines (including pediatric entities such as medulloblastoma, neuroblastoma and Ewing sarcoma) from the Cancer Cell Line Encyclopedia (CCLE, Broad Institute, Cambridge, MA, USA) and the DepMap portal with PRIMA-1 sensitivity data obtained from the |